TY  - JOUR
AU  - Kohle, Felix
AU  - Wunderlich, Gilbert
AU  - Fink, Gereon R.
AU  - Schroeter, Michael
AU  - Lehmann, Helmar C.
AU  - Schneider, Christian
TI  - Rituximab in non-systemic vasculitic neuropathy: a single-center experience
JO  - Journal of neurology
VL  - 271
IS  - 7
SN  - 0367-004X
CY  - Heidelberg
PB  - Springer
M1  - FZJ-2024-03585
SP  - 4406 - 4411
PY  - 2024
N1  - Funding Open Access funding enabled and organized by Projekt DEAL. FK was supported by the Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/University of Cologne. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (Project No. 413543196).
AB  - Objectives This case series reports clinical features and outcome of four patients with non-systemic vasculitic neuropathy(NSVN) treated with the anti-CD20 agent rituximab.Methods Clinical, electrophysiological and biopsy data were retrospectively obtained and evaluated. Only patients withpathological definite or probable NSVN were included. Extensive clinical and laboratory work-up excluded systemic vasculitis.Follow-up data for at least 12 months and up to five years is provided. Outcome of the patients was assessed usingthe MRC-Sum Score, Prineas Score and Neurological Symptom Score.Results Two of four patients treated with rituximab achieved disease remission and one patient remained stable under anti-CD20 therapy after a required treatment switch due to toxic side effects of cyclophosphamide. One patient deteriorated underrituximab induction. Rituximab was well tolerated in all patients.Discussion Anti-CD20 therapy might be an alternative in NSVN patients requiring further treatment escalation or treatmentswitch due to side effects of corticosteroids or cyclophosphamide.
LB  - PUB:(DE-HGF)16
C6  - 38656623
UR  - <Go to ISI:>//WOS:001208272700002
DO  - DOI:10.1007/s00415-024-12378-1
UR  - https://juser.fz-juelich.de/record/1027019
ER  -